Results 61 to 70 of about 21,002 (145)

Calcification and tumour‐infiltrating lymphocytes predict upgrade of human epidermal growth factor 2 (HER2)‐negative ductal carcinoma in situ diagnosed on core needle biopsy

Histopathology, Volume 89, Issue 1, Page 122-135, July 2026.
With evolving paradigm in treatment of patient diagnosed with pure ductal carcinoma in situ (DCIS), it is essential to stratify patients at low risk for upgrade to invasive disease at subsequent excision to inform management decisions. When combined with adequate sampling and intrinsic tumour characteristics, tumour microenvironment (TME) features ...
Monalyn Marabi, Yuyang Li, Chaiwat Aphivatanasiri, Julia Y Tsang, Joshua JX Li, Lin‐Ying Chen, Gary M Tse   +6 more
wiley   +1 more source

Different distribution of breast cancer subtypes in breast ductal carcinoma in situ and ductal carcinoma in situ with microinvasion

Zhongguo aizheng zazhi, 2018
Background and purpose: Breast ductal carcinoma in situ with microinvasion (DCIS-MI) is considered to be the interim stage in the progression from breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).
李　爽, 郎冠天, 余科达
doaj  

Geopolitics on a Shoestring? Unpacking the EU'S Geopolitical External Assistance to Central Asia

JCMS: Journal of Common Market Studies, Volume 64, Issue 4, Page 1473-1495, July 2026.
ABSTRACT The paper examines how the European Union's (EU) increasingly emphasised geopolitical ambitions are reflected in the practice of its external assistance policy. An analysis of EU documents around various policy initiatives and funding instruments reveals that in the Commission's understanding, geopolitical external assistance increases EU ...
Balázs Szent‐Iványi, Dóra Piroska
wiley   +1 more source

Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance

Breast Cancer Research
In many countries, hormone receptor status assessment of ductal carcinoma in situ (DCIS) is routinely performed, as hormone receptor-positive DCIS patients are eligible for adjuvant anti-hormonal treatment, aiming to reduce the ipsilateral and ...
Mieke R. Van Bockstal, Jelle Wesseling, Ester H. Lips, Marjolein Smidt, Christine Galant, Carolien H. M. van Deurzen   +5 more
doaj   +1 more source

Investigating the Impact of the Spatially Heterogeneous Surface Dust Cover on Martian Global Dust Event Occurrence

Geophysical Research Letters, Volume 53, Issue 11, 16 June 2026.
Abstract The observed inter‐annual variability of Global Dust Events (GDE) occurrence on Mars remains challenging to understand and therefore to predict. Several hypotheses have been investigated so far, but a central aspect seems to be missing: How the heterogeneity of the surface dust cover and regolith particle size distributions relate to regional ...
Demetrius Ramette, Lena Noack, Jonathan P. Merrison, Kerstin Schepanski   +3 more
wiley   +1 more source

Prognostic value of ductal carcinoma in situ component in invasive ductal carcinoma of the breast: a Surveillance, Epidemiology, and End Results database analysis

Cancer Management and Research, 2018
San-Gang Wu,1,* Wen-Wen Zhang,2,* Jia-Yuan Sun,2 Zhen-Yu He2 1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen, People’s Republic of China; 2Department of Radiation Oncology, Sun ...
Wu SG, Zhang WW, Sun JY, He ZY
doaj  

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

BMC Cancer, 2018
Background Tumour-infiltrating lymphocytes (TILs) have been demonstrated to significantly influence prognosis and response to therapy of invasive breast cancer (IBC).
Marie Beguinot, Marie-Melanie Dauplat, Fabrice Kwiatkowski, Guillaume Lebouedec, Lucie Tixier, Christophe Pomel, Frederique Penault-Llorca, Nina Radosevic-Robin   +7 more
doaj   +1 more source

Duktalinė karcinoma in situ: vieno centro patirtis ir 5 metų pooperacinė stebėsena

Lietuvos Chirurgija, 2016
Įvadas Duktalinė karcinoma in situ (DCIS) – heterogeniška liga. Įdiegus profilaktinės patikros programą, nustatomų DCIS atvejų sparčiai daugėja. Medžiaga ir metodai Atlikome retrospektyvią pacienčių, operuotų Nacionaliniame vėžio institute dėl DCIS 2010 ...
Daiva Gudavičienė, Žygimantas Židonis   +1 more
doaj  

Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials

Cancer Imaging
Background Ductal Carcinoma In Situ (DCIS) can progress to invasive breast cancer, but most DCIS lesions never will. Therefore, four clinical trials (COMET, LORIS, LORETTA, AND LORD) test whether active surveillance for women with low-risk Ductal ...
Sena Alaeikhanehshir, Madelon M. Voets, Frederieke H. van Duijnhoven, Esther H. lips, Emma J. Groen, Marja C. J. van Oirsouw, Shelley E. Hwang, Joseph Y. Lo, Jelle Wesseling, Ritse M. Mann, Jonas Teuwen, Grand Challenge PRECISION Consortium Steering Group   +11 more
doaj   +1 more source

Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ

Breast Cancer Research
Background Ductal carcinoma in-situ (DCIS) is a pre-invasive form of invasive breast cancer (IBC). Due to improved breast cancer screening, it now accounts for ~ 25% of all breast cancers. While the treatment success rates are over 90%, this comes at the
Marija Debeljak, Soonweng Cho, Bradley M. Downs, Michael Considine, Brittany Avin-McKelvey, Yongchun Wang, Phillip N. Perez, William E. Grizzle, Katherine A. Hoadley, Charles F. Lynch, Brenda Y. Hernandez, Paul J. van Diest, Wendy Cozen, Ann S. Hamilton, Debra Hawes, Edward Gabrielson, Ashley Cimino-Mathews, Liliana D. Florea, Leslie Cope, Christopher B. Umbricht   +19 more
doaj   +1 more source